Biodegradable nanoparticles for drug delivery and targeting

Current Opinion in Solid State and Materials Science

Volumn 6, Issue 4, 2002, Pages 319-327

  Hans, M L ^a   Lowman, A M ^a  

^a Drexel University   (United States)

Author keywords

Drug delivery; Nanoparticles; PLGA; Surface modifications

Indexed keywords

BIODEGRADATION; NANOSTRUCTURED MATERIALS; ONCOLOGY; POLYMERS;

DRUG DELIVERY;

DRUG THERAPY;

POLYMER;

MEDICAL APPLICATION;

BIODEGRADABILITY; CANCER THERAPY; DRUG DELIVERY SYSTEM; NANOPARTICLE;

EID: 0036707316     PISSN: 13590286     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-0286(02)00117-1     Document Type: Article

References (49)

1. Aprahamian M, et al. Transmucosal passage of poly-alkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine. Biol Cell 1987;61:69-76.
2. Soppimath KS, et al. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70:1-20.
3. Florence AT. The oral absorption of micro- and nanoparticulates: neither exceptional nor unsual Pharm Res 1997;14(3):259-66
4. Florence AT, Hussain N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv Drug Deliv Rev 2001;50:S69-89.
5. Torche A-M, et al. Ex vivo and in situ PLGA micropheres uptake by pig ileal Peyer's patch segment. Int J Pharm 2000;201:15-27.
6. Lencome D, Preat V. Polymeric nanoparticles as delivery system for influenza virus glycoproteins. J Control Release 1998;54:15-27.
7. Blanco MD, Alonso MJ. Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres. Eur J Pharm Biopharm 1997;43: 287-94.
8. Sun H et al. Regulation of smooth muscle cell proliferation using paclitaxel loaded poly(ethylene oxide)-poly(lactide/glycolide) nanopheres. J Biomed Mater Res 1998;42:331-8.
9. Song CX, et al. Formulation and characerizaion of biodegradable nanoparticles for intravascular local drug delivery. J Control Release 1997;43:197-212
10. Cheng Y-H, Illum L, Davis SS. A poly(D,L-lactide-co-glycolide) microsphere depot system for delivery of haloperidol. J Control Release 1998;55:203-12.
11. Feng S-S, Huang G. Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J Control Release 2001;71:53-69
12. Vila A, et al. Design of biodegradable particles for protein delivery. J Control Release 2002;78:15-24
13. Rafati H, et al. Protein loaded Poly (DL-lactide-co-glycolide) microparticles for oral administration: formulation, stuctural and release characteristics. J Control Release 1997;43:89-102.
14. Li Y-P, et al. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodisribution in rats. J Control Release 2001;71:203-11.
15. Carino GP, Jacob JS, Mathiowitz E. Nanosphere pased oral insulin delivery. J Control Release 2000;65:261-9.
16. Kwon H-Y, et al. Preparation of PLGA nanoparticles containing estrogen by emulsification-diffusion method. Colloids Surf 2001;182:123-30.
17. Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Delivery 2001;47:39-54.
18. Govender T, et al. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release 1999;57:171-85.
19. Murakami H, et al. Preparation of poly(DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Pharm 1999;187:143-52.
20. Verger ML-L, et al. Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur J Pharm Biopharm 1998;46:137-43.
21. Leroux J-C, et al. Biodegradable nanoparticles-from sustained release formulations to improved site specific drug delivery. J Control Release 1996;39:339-50.
22. Sakuma S, Hayashi M, Akashic M. Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv Drug Delivery 2001;47:21-37.
23. Behan N, Birkenshaw C, Clarke N. Poly n-butyl cyanoacrylate nanoparticles: a mechanistic study of polymerisation and particle formation. Biormaterials 2001;22:1335-44.
24. Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv 2001;47:83-97.
25. Hu Y. et al. Synthesis and characterization of chitosan-poly(acrylic acid) nanoparticles. Biomaterials, in press.
26. Fontana G, et al. Preparation, charaterization and in vitro anti-microbial activity of ampicillin-loaded polyethylcyanoacrylate nanoparticles. Biomaterials 1998;19:1009-17.
27. Chacon M, et al. Stability and freeze-drying of cyclosporine loaded poly (D,L-lactide-glycolide) carriers. Eur J Pharm Sci 1999;8:99-107.
28. Saez A, et al. Freeze-drying of polycarolactone and poly(D,L-lactic-glycolic) nanoparticles induces minor particle size changes affecting the oral pharmacokinetics of loaded drugs. Eur J Pharm Biopharm 2000;50:379-87.
29. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv 2001;47:65-81.
30. Arias JL, et al. Synthesis and characterization of poly(ethyl-2-cyanoacrylate) nanoparticles. J Control Release 2001;77: 309-21.
31. Fontana G, et al. Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: influence of PEG coating on the particle size, drug release rate and phagocytic uptake. Biomaterials 2001;22:2857-65.
32. Jung T, Breitenbach A, Kissel T, Sulfolbutylated poly(vinyl alcohol)- graft-poly(lactide-co-glycolide)s facilitate the preparation of small negatively charged biodegradable nanospheres. J Control Release 2000;67: 157-69.
33. Yoo HS, et al. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Control Release 2000;68:419-31.
34. Nicoli S, et al. Design of triptorelin loaded nanospheres for transdermal iontophoretic administration. Int J Pharm 2001;214:31-5.
35. Muller RE, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv 2001;47:3-19.
36. Gref R, et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption Colloids Surf B 2000;18:301-13.
37. Ferro M, et al. The role of PEG on the stability in digestive fluids and in vivo hate of PER PLA nanoparticles following oral administration. Colloids Surf B 2000;18:315-23.
38. Perat MIT, et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release 1999;60:121-8.
39. Panagi Z, et al. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Intl J Pharm 2001; 221:143-52
40. Redhead HM, Davis SS, Illum L. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908 in vitro characterization and in vivo evaluation. J Control Release 2001;70:353-63.
41. Fishbein I, et al. Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. J Control Release 2000;65: 221-9.
42. Song C, et al. Afterial uptake of biodegradable nanoparticles for intravascular local drug delivery: Results with an acute dog model. J Control Release 1998;54:201-11.
43. Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv 2001;47:55-64.
44. Lambert G, Fattal E, Couvreur P. Nanoparticulate systems for the delivery of antisense oligonucleotides. Adv Drug Deliv 2001;47:99-112
45. Perez C, et al. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J Control Release 2001;75:211-24.
46. Illum L, et al. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001;51:81-96.
47. DeCampos A, Sanchez A, Alonso M. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface Application to cyclosporin A. Int J Pharm 2001;224:159-68.
48. Matsumoto J, et al. Preparation of nanoparticles consisted of poly(L-lactide)-poly(ethylene glycol)-poly(L-lactide) and their evolution in vitro. Int J Pharm 1999;185:93-101.
49. Avgoustakis K, et al. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vivo drug release and in vivo drug residence in blood properties. J Control Release 2002;79:123-35.